Research has shown that psychedelic drugs such as psilocybin and MDMA may offer significant benefit for patients struggling at the end of life and those with major depressions and treatment-resistant PTSD. This 1-day conference will bring together doctors, scientific researchers, attorneys and ethicists to consider the medical, legal and ethical implications of this evolving research.
When: Friday, October 27, 2017 - 8:30AM – 5PM
Where: UW School of Law, William H. Gates Hall, Seattle
Registration: Registration is required to attend, and includes lunch. Early-bird rates end Sept. 10. https://www.law.uw.edu/events/psychedelic-medicine/
$225.00 Early General (by Sept. 10, 2017)
$275.00 Standard General (after Sept. 10, 2017)
$125.00 Early Non-Profit & Government (by Sept. 10, 2017)
$175.00 Standard Non-Profit & Government (after Sept. 10, 2017)
Featured speakers include MAPS Executive Director Rick Doblin, Washington State Rep. Roger Goodman, End of Life Liberty Project Executive Director Kathryn Tucker, and Ethan Nadelmann, founder of the Drug Policy Alliance.
Full list of speakers: https://www.law.uw.edu/events/psychedelic-medicine/symposium-speakers/
Sponsors: UW Center for Law, Science and Global Health, the End of Life Liberty Project, and the Drug Policy Alliance.